Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368168 | 0.77 | MEN1 (1.00) | MEN1LMNACYP1A2MAPK1BLM | |
| SCHEMBL499903 | 0.77 | MEN1 (1.00) | MEN1LMNACYP1A2MAPK1BLM | |
| SCHEMBL499904 | 0.77 | MEN1 (1.00) | MEN1LMNACYP1A2MAPK1BLM | |
| SCHEMBL31202552 | 0.77 | MEN1 (1.00) | MEN1LMNACYP1A2MAPK1BLM | |
| SCHEMBL499902 | 0.77 | MEN1 (1.00) | MEN1LMNACYP1A2MAPK1BLM | |
| SCHEMBL8337186 | 0.70 | GRIN1 (0.41) | MEN1LMNACYP1A2MAPK1BLM | |
| SCHEMBL8752564 | 0.68 | MEN1 (0.72) | MEN1LMNACYP1A2MAPK1BLM | |
| SCHEMBL8958735 | 0.68 | MEN1 (0.61) | MEN1LMNACYP1A2MAPK1BLM | |
| SCHEMBL8958740 | 0.68 | MEN1 (0.61) | MEN1LMNACYP1A2MAPK1BLM | |
| SCHEMBL27451323 | 0.65 | KMT2A (0.50) | MEN1LMNACYP1A2MAPK1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004039371-A2 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF NEUROPATHIC PAIN | PHARMACIA CORPORATION (US) | 2004-05-13 | — | — | WO | disclosed |